Guided Therapeutics (GTHP)

Executive Summary

Guided Therapeutics, Inc. (OTC: GTHP) is a diagnostics company focused on developing a patented biophotonic platform for early detection of diseases, particularly in oncology. The company's technology aims to provide more accurate and efficient screening compared to existing methods. Founded in 1992 and headquartered in Norcross, Georgia, Guided Therapeutics has a market valuation of approximately $19 million based on 96 million shares outstanding. Despite a long history, the company remains in early commercial stages with no disclosed revenue or FDA approvals. The core product, a noninvasive cervical cancer screening device using biophotonic technology, targets a large market but faces competition from established HPV and Pap tests. Recent efforts have centered on regulatory pathways and potential partnerships to advance commercialization. The lack of recent financial or clinical updates suggests the company is pre-revenue with significant execution risk. However, if successful, the technology could disrupt traditional screening methods, offering a rapid, point-of-care alternative. Investors should monitor regulatory filings and clinical trial outcomes closely.

Upcoming Catalysts (preview)

• TBDFDA 510(k) Clearance or De Novo Classification for Cervical Cancer Screening Device20% success
• TBDPublication of Pivotal Clinical Study Results Demonstrating Sensitivity/Specificity25% success
• TBDStrategic Partnership or Licensing Agreement with a Diagnostic OEM15% success